Advertisement
The new Pharmacor report entitled Benign Prostatic Hyperplasia finds thatthe market to treat the disease is dominated by two drug classes -- alphablockers and 5-alpha-reductase inhibitors -- which make up 93% of drug salesin the United States, France, Germany, Italy, Spain, the United Kingdom, andJapan. Boehringer Ingelheim's Flomax and Astellas's Omix (both alpha blockers)dominated the market in 2006, comprising half of all benign prostatichyperplasia drug sales. However, the patent expiries of Proscar, Flomax, Omix,and GlaxoSmithKline's Avodart in the United States in 2009 will cause asignificant decline in the overall benign prostatic hyperplasia market by2011.
Advertisement
Although patent expiries will constrain the market in the near term,increases in the patient population, unmet need, and higher drug treatmentrates from 2011 to 2016 will help create a favorable landscape for novelbenign prostatic hyperplasia treatments.
"Eli Lilly's Cialis and GlaxoSmithKline's fixed-dose combination oftamsulosin and dutasteride, both of which are expected to launch for benignprostatic hyperplasia in the United States and in Europe by 2011, are the twomost promising agents in the pipeline," said Greg Dwyer, analyst at DecisionResources. "The combined sales of these two drugs will represent nearly 30% ofthe total benign prostatic hyperplasia market in 2016."
To listen to an interview with Mr. Dwyer regarding the benign prostatichyperplasia drug market, please visit the Find Out More section of theDecision Resources home page on September 17, 2007, athttp://www.DecisionResources.com.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources
